SPECIFIC PROCUREMENT FOR THE SUPPLY OF ACTIVE PRINCIPLES – “ADALIMUMAB” AND “HUMAN C1 ESTERASE INHIBITOR” DIVIDED INTO 2 LOTS, THROUGH THE USE OF THE SINTEL PLATFORM WITHIN THE DYNAMIC ACQUISITION SYSTEM FOR PHARMACEUTICAL PRODUCT SUPPLIES ARIA_2025_045.

This tender concerns a specific procurement for the supply of two active pharmaceutical ingredients: Adalimumab and Human C1 Esterase Inhibitor. The procurement is structured into two distinct lots, utilizing the SINTEL platform as part of the dynamic acquisition system for pharmaceutical products, identified by the code ARIA_2025_045. The Contracting Authority for this tender is ASST OVEST MILANESE, located in Legnano, Italy. The overall estimated value for this contract was EUR 71,543.00. The procedure followed was a negotiated procedure without prior publication of a call for competition. Lot 1, with CIG BA5ED666EB, focuses on the supply of Adalimumab, with an estimated value of EUR 45,543.00. Lot 2, with CIG BA5ED677BE, pertains to the supply of Human C1 Esterase Inhibitor, estimated at EUR 26,000.00. Both lots fall under the CPV code for various medicines. The contract nature is for supplies. The awarded value for this specific procurement was EUR 41,106.00, with Celltrion Healthcare Italy S.r.l. being the selected awardee. This tender highlights the strategic acquisition of essential pharmaceutical components to meet healthcare needs within the specified region.

This is a supplies contract in the general supplies sector, with a focus on General Supplies. Located in Italy, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 71,543.

Published through ANAC (Italy), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the general supplies sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.